vTv Therapeutics (VTVT) reported Thursday screening has been reinitiated in its phase 3 trial of cadisegliatin as an adjunctive treatment of type 1 diabetes following a protocol amendment.
Continuous glucose monitors will now be provided to participants to inform the primary study endpoint, which is the number of level 2 and level 3 hypoglycemic events, the company said.
The amendment shortens trial duration to six months from 12, expediting time to topline data, the company said.
"We look forward to reporting topline Phase 3 data from CATT1 in the second half of 2026," said CEO Paul Sekhri.
The shares were up over 3% in recent trading.
Price: 21.96, Change: +0.65, Percent Change: +3.06
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。